Approval in sight, Perceptive, OrbiMed double down on Foamix's antibiotic foam to the tune of $64M

In anticipation of a long-awaited — and somewhat delayed — date with the FDA on its topical dermatology drugs, Foamix has returned to its biggest shareholders to stack up resources for the commercial stretch ahead.